J1250
J1250 – Injection, dobutamine hydrochloride, per 250 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 19 NDCs crosswalked per 250 MG $7.691/unit ASP+6%
📋 J1250 summary
J1250 is a HCPCS Level II J-code used to bill dobutamine hydrochloride, per 250 mg, billed per 250 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J1250: Dobutamine Hcl-D5W*, Dobutamine, Dobutamine Hydrochloride In Dextrose
Code J1250
Billing unit 250 MG Payment limit $7.691/unit NDC-Crosswalk 19
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ1250
DescriptorInjection, dobutamine hydrochloride, per 250 mg
Billing unit250 MG
Payment limit / unit$7.691
Est. ASP / unit$7.256 est.
Mapped NDCs19
Data periodQ3 2026
Last updated2026-08-20
💊 About Dobutamine DRUG GUIDE
Dobutamine injection is used when the heart suddenly loses its ability to pump blood effectively — a condition called cardiac decompensation.
This can happen because of organic heart disease or as a result of heart surgery.
It is given intravenously (through an IV) in a hospital or clinical setting to provide short-term inotropic support, meaning it helps the heart muscle contract more strongly.Clinical trial experience with intravenous dobutamine extends only up to 48 hours of use.
Dobutamine has not been shown to be safe or effective for long-term treatment of heart failure, and long-term use of similar drugs has been linked to increased risk of hospitalization and death.
Clinical overview from our editorial drug guide for Dobutamine. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$7.691
Est. ASP / unit
$7.256 est.
Est. after 2% sequester
$7.537
HCPCS dosage
250 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, dobutamine hydrochloride, per 250 mg
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date1997-01-01
Date added1996-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J1250 = 250 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J1250 WITH EST. MEDICARE PAY
19 NDCs map to J1250. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($7.691/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00143-9141-10 | Dobutamine 12.5 mg/mL INJECTION, SOLUTION | Hikma | 10 VIAL in 1 CARTON (0143-9141-10) / 20 m... | 12.5 mg/mL | 10 | $76.91 | — | ● Active | CMS + PDAC |
| 00338-1073-02 | Dobutamine Hydrochloride in Dextrose 100 mg/100mL INJECTION | Baxter | 18 BAG in 1 CARTON (0338-1073-02) / 250 m... | 100 mg/100mL | 18 | $138.44 | — | ● Active | CMS + PDAC |
| 00338-1075-02 | Dobutamine Hydrochloride in Dextrose 200 mg/100mL INJECTION | Baxter | 18 BAG in 1 CARTON (0338-1075-02) / 250 m... | 200 mg/100mL | 36 | $276.88 | — | ● Active | CMS + PDAC |
| 00338-1077-02 | Dobutamine Hydrochloride in Dextrose 400 mg/100mL INJECTION | Baxter | 18 BAG in 1 CARTON (0338-1077-02) / 250 m... | 400 mg/100mL | 72 | $553.75 | — | ● Active | CMS + PDAC |
| 00409-2344-01 | DOBUTAMINE 12.5 mg/mL INJECTION, SOLUTION, CONCENTRATE | Hospira, | 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-2344... | 12.5 mg/mL | 1 | $7.69 | — | ● Active | CMS + PDAC |
| 00409-2344-02 | DOBUTAMINE 12.5 mg/mL INJECTION, SOLUTION, CONCENTRATE | Hospira, | 10 VIAL, SINGLE-DOSE in 1 TRAY (0409-2344-... | 12.5 mg/mL | 10 | $76.91 | — | ● Active | CMS + PDAC |
| 00409-2344-88 | DOBUTAMINE 12.5 mg/mL INJECTION, SOLUTION, CONCENTRATE | Hospira, | 10 VIAL, SINGLE-DOSE in 1 TRAY (0409-2344-... | 12.5 mg/mL | 10 | $76.91 | — | ● Active | CMS + PDAC |
| 50090-4562-00 | Dobutamine HCl | A-S | — | — | 4 | $30.76 | — | — | CMS ASP |
| 51662-1330-01 | DOBUTAMINE 200 mg/100mL INJECTION, SOLUTION | HF | 250 mL in 1 BAG (51662-1330-1) | 200 mg/100mL | 2 | $15.38 | — | Obsolete | CMS ASP |
| 51662-1337-01 | DOBUTAMINE 12.5 mg/mL INJECTION, SOLUTION, CONCENTRATE | HF | 20 mL in 1 VIAL, SINGLE-DOSE (51662-1337-1... | 12.5 mg/mL | 1 | $7.69 | — | ● Active | CMS ASP |
| 51662-1337-03 | DOBUTAMINE 12.5 mg/mL INJECTION, SOLUTION, CONCENTRATE | HF | 10 POUCH in 1 CASE (51662-1337-3) / 1 VIA... | 12.5 mg/mL | 10 | $76.91 | — | ● Active | CMS ASP |
| 51662-1566-01 | DOBUTAMINE HYDROCHLORIDE 100 mg/100mL INJECTION | HF | 250 mL in 1 BAG (51662-1566-1) | 100 mg/100mL | 1 | $7.69 | — | ● Active | CMS ASP |
| 70436-0203-80 | Dobutamine 250 mg/20mL INJECTION | Slate | 1 VIAL, SINGLE-DOSE in 1 CARTON (70436-203... | 250 mg/20mL | 1 | $7.69 | — | ● Active | CMS + PDAC |
| 70436-0203-82 | Dobutamine 250 mg/20mL INJECTION | Slate | 10 VIAL, SINGLE-DOSE in 1 CARTON (70436-20... | 250 mg/20mL | 10 | $76.91 | — | ● Active | CMS + PDAC |
| 00409-2347-32 | DEXTROSE/DOBUTAMINE (LATEX-FREE) 5%-200 MG/100 ML | Unknown | — | — | 0.008 | $0.06 | — | — | PDAC |
| 00409-3724-32 | DEXTROSE/DOBUTAMINE (LATEX-FREE) 5%-400 MG/100 ML | Unknown | — | — | 0.016 | $0.12 | — | — | PDAC |
| 00409-2346-32 | DOBUTAMINE IN DEXTROSE (12X250ML,LATEX-FREE) 5%-100 MG/100 ML | Unknown | — | — | 0.004 | $0.03 | — | — | PDAC |
| 00409-2025-20 | DOBUTAMINE (10X20ML) 12.5 MG/ML | Unknown | — | — | 0.05 | $0.38 | — | — | PDAC |
| 00409-2025-54 | DOBUTAMINE HCL (10X40ML) 12.5 MG/ML | Unknown | — | — | 0.05 | $0.38 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$183.5K
Claims
2,155
Beneficiaries
866
Spend / beneficiary
$211.92
Spend / claim
$85.16
Trend by period
Where J1250 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #533 of 824
#528
ENVERSE, PER SQ CM** Q4258
$195.1K
#529
FLEXHD** Q4128
$193.7K
#530
IPRATROPIUM BROMIDE J7644
$193.1K
#531
CUBICIN RF* J0878
$192.9K
#532
AMNIO TRI-CORE, PER... Q4295
$191.6K
#533
DOBUTAMINE HCL-D5W* J1250
$183.5K
#534
TROGARZO J1746
$183.1K
#535
AXOLOTL DUALGRAFT, P... Q4332
$182.5K
#536
FIBRYGA J7177
$178.7K
#537
AMNIOBAND, GUARDIAN... Q4151
$163K
#538
VALRUBICIN* J9357
$159K
Total claims — #303 of 824
#298
ACETYLCYSTEINE J7608
2,256
#299
MOXIFLOXACIN J2280
2,225
#300
TALVEY J3055
2,180
#301
AVSOLA Q5121
2,176
#302
PEMFEXY J9304
2,157
#303
DOBUTAMINE HCL-D5W* J1250
2,155
#304
AVGEMSI J9184
2,143
#305
FERRLECIT* J2916
2,139
#306
CYCLOPHOSPHAMIDE(J85... J8530
2,107
#307
XEMBIFY J1558
2,103
#308
CYCLOPHOSPHAMIDE(J90... J9071
2,094
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $183.5K | 866 | 2,155 | $211.92 | $85.16 |
| 2025 (Q1-Q4) | $729.7K | 3,137 | 9,055 | $232.63 | $80.59 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$735.9K
Medicare paid
$575.1K
Submitted services
140,835
Denial rate
27.1%
Allowed / service
$7.16
Submitted charges
$4.51M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J1250 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 2,250 services across 25 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
📊 What bills under J1250
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
19 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J1250 billing FAQ
What is HCPCS code J1250?
J1250 is a HCPCS Level II J-code used to bill Injection, dobutamine hydrochloride, per 250 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J1250?
One unit of J1250 represents 250 MG. Report the number of units equal to the dose administered divided by 250 MG.
How many units of J1250 should I bill?
Divide the dose administered by the code's unit size (250 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J1250?
The Medicare Part B payment limit is $7.691 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $7.537 per unit. Payment limits are revised quarterly.
Which NDCs bill under J1250?
19 NDCs currently map to J1250 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J1250 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.